Erlotinib (Tarceva, OSI Pharmaceuticals, Long Island, NY, USA), another small molecule inhibitor of EGFR, demonstrated a 6% partial response rate in a multicentre phase II trial with EGFR-positive ovarian cancer patients with taxane- and/or platinum-refractory or -resistant disease. This evidence concerns the gene EGFR and ovarian cancer.